Similar beneficial outcomes have been demonstrated following AAV-mediated overexpression of human GCase in the CNS of Gba mutant homozygous mice; providing further validation that modulating GCase-related sphingolipid metabolism may be a viable therapeutic strategy for improving the proteinopathy and pathological phenotypes in synucleinopathies23. Here, GBA1 is linked to proteostasis deficiencies.